Bortezomib [clinicaltrials_resource:e28b6867d67df196e61715b986db5f30]
condition [clinicaltrials_vocabulary:condition]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome [clinicaltrials:NCT00005064]Bortezomib in Treating Patients With Recurrent Glioma [clinicaltrials:NCT00006773]Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery [clinicaltrials:NCT00007878]Bortezomib in Treating Children With Advanced Solid Tumors [clinicaltrials:NCT00021216]clinicaltrials:NCT00023712clinicaltrials:NCT00023764Bortezomib in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00023881]PS-341 in Treating Patients With Metastatic Malignant Melanoma [clinicaltrials:NCT00024011]clinicaltrials:NCT00025376PS-341 in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00025584]Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma [clinicaltrials:NCT00027716]Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00027898]PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00028587]Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00028912]Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors [clinicaltrials:NCT00030368]Bortezomib in Treating Patients With Mantle Cell Lymphoma [clinicaltrials:NCT00030875]clinicaltrials:NCT00038571Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer [clinicaltrials:NCT00040768]clinicaltrials:NCT00045695Phase 2 Study of VELCADE Alone or VELCADEĀ® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer [clinicaltrials:NCT00051974]Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma [clinicaltrials:NCT00051987]Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer [clinicaltrials:NCT00052338]Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer [clinicaltrials:NCT00052507]Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer [clinicaltrials:NCT00052689]Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction [clinicaltrials:NCT00054483]clinicaltrials:NCT00054665clinicaltrials:NCT00059618clinicaltrials:NCT00059631clinicaltrials:NCT00061932VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma [clinicaltrials:NCT00063713]clinicaltrials:NCT00064012Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter [clinicaltrials:NCT00066352]Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy [clinicaltrials:NCT00066508]Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer [clinicaltrials:NCT00066625]Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy [clinicaltrials:NCT00068289]Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [clinicaltrials:NCT00068315]A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies [clinicaltrials:NCT00068484]Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma [clinicaltrials:NCT00072150]Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [clinicaltrials:NCT00074009]Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer [clinicaltrials:NCT00075751]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Bortezomib [clinicaltrials_resource:e28b6867d67df196e61715b986db5f30]
Bio2RDF identifier
e28b6867d67df196e61715b986db5f30
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e28b6867d67df196e61715b986db5f30
identifier
clinicaltrials_resource:e28b6867d67df196e61715b986db5f30
title
Bortezomib
@en
type
label
Bortezomib [clinicaltrials_resource:e28b6867d67df196e61715b986db5f30]
@en